EP1009434A4 - Stabilisatoren mit rekombinanten menschlichen serumalbumin für lebend virusvakzine - Google Patents
Stabilisatoren mit rekombinanten menschlichen serumalbumin für lebend virusvakzineInfo
- Publication number
- EP1009434A4 EP1009434A4 EP98942336A EP98942336A EP1009434A4 EP 1009434 A4 EP1009434 A4 EP 1009434A4 EP 98942336 A EP98942336 A EP 98942336A EP 98942336 A EP98942336 A EP 98942336A EP 1009434 A4 EP1009434 A4 EP 1009434A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- serum albumin
- human serum
- recombinant human
- live virus
- containing recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0015—Combination vaccines based on measles-mumps-rubella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/20—Rubella virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5793797P | 1997-09-05 | 1997-09-05 | |
US57937P | 1997-09-05 | ||
PCT/US1998/018100 WO1999012568A1 (en) | 1997-09-05 | 1998-09-01 | Stabilizers containing recombinant human serum albumin for live virus vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1009434A1 EP1009434A1 (de) | 2000-06-21 |
EP1009434A4 true EP1009434A4 (de) | 2006-07-05 |
Family
ID=22013663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98942336A Withdrawn EP1009434A4 (de) | 1997-09-05 | 1998-09-01 | Stabilisatoren mit rekombinanten menschlichen serumalbumin für lebend virusvakzine |
Country Status (6)
Country | Link |
---|---|
US (1) | US6210683B1 (de) |
EP (1) | EP1009434A4 (de) |
JP (1) | JP2001518447A (de) |
AU (1) | AU735330B2 (de) |
CA (1) | CA2302282A1 (de) |
WO (1) | WO1999012568A1 (de) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403098B1 (en) * | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
ES2383640T3 (es) | 1996-11-20 | 2012-06-25 | Crucell Holland B.V. | Composiciones de adenovirus que pueden obtenerse mediante un método de producción y purificación mejorado |
US20060275781A1 (en) | 2004-11-03 | 2006-12-07 | Introgen Therapeutics Inc. | Novel method for the protection and purification of adenoviral vectors |
CN1053590C (zh) * | 1998-10-19 | 2000-06-21 | 卫生部长春生物制品研究所 | 冻干甲型肝炎减毒活疫苗及其保护剂 |
EP1133316B1 (de) * | 1998-11-16 | 2009-01-21 | Introgen Therapeutics, Inc. | Adenovirus-formulierungen zur gentherapie |
US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
FR2791895B1 (fr) * | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
WO2001034646A2 (en) * | 1999-11-12 | 2001-05-17 | Fibrogen, Inc. | Recombinant gelatins |
ES2237551T3 (es) * | 2000-02-08 | 2005-08-01 | Allergan, Inc. | Composiciones farmaceuticas que contienen toxina botulinica. |
US20040052800A1 (en) * | 2000-08-07 | 2004-03-18 | Bruce Carpick | Stabilization of immunogens derived from paramyxoviruses |
JP2004238392A (ja) * | 2003-01-14 | 2004-08-26 | Nipro Corp | 安定化された蛋白質性製剤 |
WO2004113518A1 (en) * | 2003-06-20 | 2004-12-29 | Microbix Biosystems Inc. | Improvements in virus production |
CA2555412C (en) | 2004-02-23 | 2013-06-25 | Crucell Holland B.V. | Virus purification methods |
FR2866890B1 (fr) | 2004-02-27 | 2008-04-04 | Lab Francais Du Fractionnement | Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant |
EP1765385A4 (de) * | 2004-06-16 | 2008-08-27 | Smart Drug Systems Inc | Impstoffzusammensetzung mit verzögerter freisetzung |
WO2006012092A2 (en) * | 2004-06-29 | 2006-02-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Safer attenuated virus vaccines with missing or diminished latency of infection |
AU2005317828A1 (en) * | 2004-12-23 | 2006-06-29 | Novozymes Delta Limited | Gene expression technique |
WO2006108707A1 (en) | 2005-04-11 | 2006-10-19 | Crucell Holland B.V. | Virus purification using ultrafiltration |
EP1907537A4 (de) * | 2005-07-14 | 2010-11-10 | Mayo Foundation | Paramyxoviridae-virus-zubereitungen |
GB2451216B (en) * | 2006-05-12 | 2011-05-04 | Bharat Biotech Int Ltd | A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein |
EP2535058A3 (de) * | 2006-11-07 | 2013-04-10 | Sanofi Pasteur Biologics, LLC | Stabilisierung von Impfstoffen durch Lyophilisierung |
US10166285B2 (en) | 2006-11-09 | 2019-01-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant virus with diminished latency and methods of using same |
KR20150082667A (ko) | 2007-04-06 | 2015-07-15 | 인비라젠 인코포레이티드 | 살아있는 약독화된 바이러스를 위한 방법 및 조성물 |
US20080294361A1 (en) * | 2007-05-24 | 2008-11-27 | Popp Shane M | Intelligent execution system for the monitoring and execution of vaccine manufacturing |
EP2254594B1 (de) | 2008-03-05 | 2015-06-03 | Sanofi Pasteur | Stabilisierungsverfahren für eine adjuvanshaltige impfstoffzusammensetzung |
EP2143440A1 (de) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Stabilisierungssubstanz und Impfzusammensetzung, die ein oder mehrere abgeschwächte lebende Flaviviridae enthält |
US10041049B2 (en) | 2008-11-03 | 2018-08-07 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
CN101768206B (zh) * | 2008-12-31 | 2013-05-15 | 华北制药集团新药研究开发有限责任公司 | 一种重组人血清白蛋白的纯化方法及其应用 |
CN102470170B (zh) * | 2009-07-13 | 2015-03-18 | 巴拉特生物技术国际有限公司 | 用作轮状病毒疫苗的组合物及其方法 |
WO2011091350A2 (en) * | 2010-01-25 | 2011-07-28 | Ventria Bioscience | Methods & compositions for improving protein production |
CN102762721B (zh) | 2010-02-15 | 2015-03-11 | 克鲁塞尔荷兰公司 | 用于生产Ad26腺病毒载体的方法 |
CN103118702A (zh) | 2010-09-20 | 2013-05-22 | 克鲁塞尔荷兰公司 | 活动性结核病的治疗性接种 |
CA2809463C (en) | 2010-09-27 | 2021-05-25 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
CA2865551C (en) | 2012-03-05 | 2021-01-12 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport | Methods and compositions for stabilizing dried biological materials |
PL2825640T3 (pl) | 2012-03-12 | 2016-10-31 | Partie rekombinowanych adenowirusów o zmienionych końcach | |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
CA2867950C (en) | 2012-03-22 | 2023-02-21 | Crucell Holland B.V. | Vaccine against rsv |
TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
KR20160003662A (ko) | 2013-03-14 | 2016-01-11 | 다케다 백신즈 인코포레이티드 | 생 약독화 알파바이러스 제형을 위한 조성물 및 방법 |
WO2014174018A1 (en) | 2013-04-25 | 2014-10-30 | Crucell Holland B.V. | Stabilized soluble prefusion rsv f polypeptides |
CN104117070A (zh) * | 2013-04-26 | 2014-10-29 | 辽宁茂康源生物科技有限公司 | 一种含山梨醇成分的水痘疫苗冻干保护剂 |
CA2914792C (en) | 2013-06-17 | 2024-02-27 | Crucell Holland B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
CN104188923A (zh) * | 2014-08-25 | 2014-12-10 | 北京合康源生物科技有限公司 | 一种新型冻干水痘减毒活疫苗的生产方法 |
KR20230107375A (ko) * | 2014-12-18 | 2023-07-14 | 암젠 인크 | 안정한 동결된 단순 포진 바이러스 제제 |
PL3283634T3 (pl) | 2015-04-14 | 2019-10-31 | Janssen Vaccines & Prevention Bv | Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem |
CN104984357B (zh) | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | 不含明胶的疫苗保护剂组合物及流感减毒活疫苗 |
EP3319634B1 (de) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilisierte lösliche präfusionierte rsv-f-polypeptide |
AU2016289492B2 (en) | 2015-07-07 | 2022-08-11 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
KR102500970B1 (ko) | 2016-04-05 | 2023-02-17 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
HUE053027T2 (hu) | 2016-04-05 | 2021-06-28 | Janssen Vaccines & Prevention Bv | Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra |
DK3464331T3 (da) | 2016-05-30 | 2021-01-18 | Janssen Vaccines & Prevention Bv | Stabiliserede præfusions-rsv f-proteiner |
BR112018075969A2 (pt) | 2016-06-20 | 2019-04-02 | Janssen Vaccines & Prevention B.V. | promotor bidirecional potente e equilibrado |
EP3484506A1 (de) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv-impfstoffe |
WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
EP3624844A1 (de) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen |
CN107432931B (zh) * | 2017-08-03 | 2018-04-13 | 长春祈健生物制品有限公司 | 一种微载体培养水痘病毒制备疫苗的方法 |
US20200308550A1 (en) | 2017-09-11 | 2020-10-01 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Tumor organoid model |
SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
CA3124690A1 (en) * | 2018-12-27 | 2020-07-02 | Amgen Inc. | Lyophilized virus formulations |
TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗 |
EP4117722A1 (de) * | 2020-03-12 | 2023-01-18 | Bavarian Nordic A/S | Zusammensetzungen zur verbesserung der pockenvirusstabilität |
WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
CN115227811B (zh) * | 2022-08-26 | 2023-07-28 | 上海荣盛生物药业股份有限公司 | 一种水痘-带状疱疹病毒活疫苗原液的制备方法 |
CN117442714A (zh) * | 2023-12-26 | 2024-01-26 | 成都柏奥特克生物科技股份有限公司 | 一种新型水痘减毒活疫苗及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3783098A (en) | 1971-08-10 | 1974-01-01 | Cornell Res Foundation Inc | Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same |
US3915794A (en) | 1973-02-09 | 1975-10-28 | Rit Rech Ind Therapeut | Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them |
US4000256A (en) | 1975-04-30 | 1976-12-28 | Merck & Co., Inc. | Varicella vaccine and process for its preparation |
US4147772A (en) | 1976-02-03 | 1979-04-03 | Merck & Co., Inc. | Vaccine stabilizer |
US4273762A (en) | 1979-12-03 | 1981-06-16 | Merck & Co., Inc. | Lyophilization process for live viral compositions |
US4337242A (en) | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
US4338335A (en) | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
JPS577423A (en) | 1980-06-13 | 1982-01-14 | Takeda Chem Ind Ltd | Frozen or freeze-dried live measles vaccine |
US5098704A (en) | 1984-06-18 | 1992-03-24 | Chiron Corporation | Hepatitis surface antigen particle vaccine |
US4952674A (en) | 1986-05-02 | 1990-08-28 | Merck & Co., Inc. | Vaccine against varicella-zoster virus |
JPS6314729A (ja) | 1986-06-30 | 1988-01-21 | スミスクライン・バイオロジカルス・ソシエテ・アノニム | 生ワクチン用改良安定剤、その製造法およびそれを含有するワクチン |
US5024836A (en) | 1987-05-04 | 1991-06-18 | Merck & Co., Inc. | Stable lyophilized live herpes virus vaccine |
JPS63307827A (ja) | 1987-06-08 | 1988-12-15 | Kitasato Inst:The | 安定化された生ウイルスワクチンおよびその製造法 |
FR2633518B1 (fr) | 1988-06-30 | 1991-03-22 | Merieux Inst | Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues |
CA2075521C (en) | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Stabilized live vaccine |
US5360736A (en) | 1992-06-04 | 1994-11-01 | Merck & Co., Inc. | Process for attenuated varicella zoster virus vaccine production |
CA2097019C (en) | 1992-06-04 | 2007-07-24 | Philip J. Provost | Process for attenuated varicella zoster virus vaccine production |
AU725231B2 (en) | 1996-12-20 | 2000-10-12 | Merck & Co., Inc. | Stabilisers for lyophilised vaccines |
-
1998
- 1998-08-26 US US09/140,428 patent/US6210683B1/en not_active Expired - Fee Related
- 1998-09-01 WO PCT/US1998/018100 patent/WO1999012568A1/en not_active Application Discontinuation
- 1998-09-01 EP EP98942336A patent/EP1009434A4/de not_active Withdrawn
- 1998-09-01 JP JP2000510465A patent/JP2001518447A/ja active Pending
- 1998-09-01 AU AU90415/98A patent/AU735330B2/en not_active Ceased
- 1998-09-01 CA CA002302282A patent/CA2302282A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO9912568A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2302282A1 (en) | 1999-03-18 |
AU9041598A (en) | 1999-03-29 |
US6210683B1 (en) | 2001-04-03 |
JP2001518447A (ja) | 2001-10-16 |
AU735330B2 (en) | 2001-07-05 |
WO1999012568A1 (en) | 1999-03-18 |
EP1009434A1 (de) | 2000-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1009434A4 (de) | Stabilisatoren mit rekombinanten menschlichen serumalbumin für lebend virusvakzine | |
ATE275631T1 (de) | Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff | |
IL181468A0 (en) | E2 subunit vaccine comprising recombinant pestivirus e2 protein | |
ZA991662B (en) | Recombinant and adjuvant-containing live vaccines. | |
GB2245272B (en) | Recombinant virus selection system | |
GB9303023D0 (en) | Flavivirus recombinant poxvirus vaccine | |
NO20001240D0 (no) | Kay-A immunsystemprotein | |
EP1021202A4 (de) | Immunogene peptide aus dem hpv e7 protein | |
FR2620459B1 (fr) | Virus recombinant de la vaccine | |
HU912526D0 (en) | Recombinant marek-type disease virus | |
HUP9902710A3 (en) | Recombinant swinepox virus | |
ZA9811316B (en) | Novel hepatitis C virus NS5B protein | |
GB2264949B (en) | Measles virus recombinant poxvirus vaccine | |
HUP9801266A3 (en) | Multimeric, recombinant urease vaccine | |
NZ298224A (en) | Recombinant papilloma virus antigens | |
IL131212A0 (en) | Recombinant virus and live-virus vaccines | |
ZA9711436B (en) | Stabilizers for lyophilized vaccines | |
EP0747482A3 (de) | Rekombinante Proteine des Hepatitis GB Virus ihre Verwendungen | |
IL101639A0 (en) | Recombinant influenza vaccines | |
EP1100545A4 (de) | Regulierte expression von rekombinanten proteinen unter verwendung von rns-viren | |
ID26951A (id) | Vaksin mycoplasma hyopneumontae recombinan | |
IL122412A0 (en) | Recombinant viral nucleic acids | |
IL116118A0 (en) | Papaya ringspot virus coat protein gene | |
EP0598759A4 (de) | Rekombinanter infektiöser rinder rhinotracheitis virus. | |
AU4489896A (en) | Avian recombinant live vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000405 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20000405;LT PAYMENT 20000405;LV PAYMENT 20000405;MK PAYMENT 20000405;RO PAYMENT 20000405;SI PAYMENT 20000405 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060602 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20061027 |